Stavroula A. Paschou, Gerasimos Siasos*, Evanthia Bletsa, Panagiota K. Stampouloglou, Evangelos Oikonomou, Alexios S. Antonopoulos, Konstantinos Batzias, Vasiliki Tsigkou, Konstantinos Mourouzis, Andromachi Vryonidou, Nikolaos Tentolouris, Manolis Vavouranakis and Dimitrios Tousoulis Pages 5980 - 5987 ( 8 )
We systematically reviewed the literature regarding the impact of dipeptidyl peptidase-4 inhibitors (DPP-4i) on vascular function, including endothelial function and arterial stiffness, as predictors of atherosclerosis progression and cardiovascular disease in patients with type 2 diabetes mellitus (T2DM). We searched PubMed in order to identify clinical trials that investigated the effect of DPP-4i on vascular function in patients with T2DM when compared with placebo. Although 168 articles were initially found, only 6 studies (total 324 patients) investigated the effect of DPP-4i in comparison with placebo, specifically linagliptin and sitagliptin, and satisfied the inclusion criteria. There are scarce data to indicate that linagliptin may enhance endothelial function and exert a slight beneficial effect on arterial wall properties. Sitagliptin seems to have a neutral effect on these variables. Further trials are needed to elucidate the topic. The standards of reporting were in accordance with the PRISMA guidelines.
Type 2 diabetes mellitus, DPP-4 inhibitors, endothelial function, arterial stiffness, cardiovascular health, molecular cardiology.
First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, First Department of Propaedeutic and Internal Medicine, Diabetes Center, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens